Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Faron Pharmaceuticals Oy
  6. News
  7. Summary
    FARN   FI4000153309

FARON PHARMACEUTICALS OY

(FARN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Faron Pharmaceuticals Oy : Updated corporate presentation

06/22/2021 | 02:01am EDT

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Updated corporate presentation

Company announcement, 22 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, has today published an updated corporate presentation on its website.

The presentation contains previously published Company information, views of Management and data from Faron's development programmes.

Latest available data from the ongoing PhI/II MATINS trial investigating bexmarilimab, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1, has been updated in the presentation to include positive incremental change to the previously reported disease control rate (DCR) in cutaneous melanoma patients. The previously reported DCR figure of 3/9 patients (33.3%) has, following the accumulation of new data, now increased to 4/11 patients (36.3%).

It should be noted that some information within the presentation may be presented in a different format or context to earlier versions. Readers are encouraged to read the corporate disclaimer on page two of the presentation. The Company may make additional non-material additions and updates to the presentation periodically, as deemed necessary, without making separate announcements of such updates.

The presentation is available to view in the Investors section of www.faron.com

Ends

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Peel Hunt LLP, Broker

Dr Christopher Golden, James Steel        

Phone: + 44 (0)20 7418 8900

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo TurnerMark Rogers

Phone. +44 (0)20 7213 0880      

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 55 38 990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

 

Stern Investor Relations

Julie Seidel

Phone: +1 212 362 1200

Email: julie.seidel@sternir.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma.  Faron is based in Turku, Finland. Further information is available at www.faron.com.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product.  In addition,  other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors.  Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is b

https://news.cision.com/faron-pharmaceuticals-oy/r/updated-corporate-presentation,c3371522

https://mb.cision.com/Main/19398/3371522/1434940.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about FARON PHARMACEUTICALS OY
10/07FARON PHARMACEUTICALS OY : Exercise of options
AQ
10/05TR-1 : Standard form for notification of major holdings
AQ
10/01FARON PHARMACEUTICALS OY : Registration of Placing Shares with Trade Register
AQ
10/01FARON PHARMACEUTICALS OY : Results of Placing and Issue Price
AQ
09/30FARON PHARMACEUTICALS OY : Proposed Issue and Placing of Shares
AQ
09/17FARON PHARMACEUTICALS OY : Presentation of Updated MATINS Data at ESMO
AQ
09/17Faron Pharmaceuticals Ltd. Announces Updated Results from the Phase I/II MATINS Study
CI
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports H1 Loss E..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports H1 Revenu..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS OY Reports H1 Rev..
MT
More news
Financials
Sales 2021 - - -
Net income 2021 -16,8 M -19,6 M -19,6 M
Net cash 2021 10,8 M 12,5 M 12,5 M
P/E ratio 2021 -13,4x
Yield 2021 -
Capitalization 214 M 249 M 249 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 56,5%
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | MarketScreener
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,01 €
Average target price 5,75 €
Spread / Average Target 43,2%
EPS Revisions
Managers and Directors
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Toni Haenninen Chief Financial Officer
Frank Murdoch Armstrong Non-Executive Chairman
Matti Karvonen Chief Medical Officer & VP-Drug Development
Jami Mandelin Research Director
Sector and Competitors
1st jan.Capi. (M$)
FARON PHARMACEUTICALS OY30.77%249
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610